Shopping Cart
Expert article · August 2026
Freeze-Dried Platelet-Rich Plasma (PRP): What Research Shows About PRP Powder
Fundamentals, manufacturing concepts, stability, clinical evidence and regulatory limits of freeze-dried PRP, platelet lysate and PFC-FD.
FD-PRPL-HPLPFC-FD
Technical article for medical professionals
“PRP powder” is not one standardized product. Depending on the process, the dried material may contain relatively intact platelets, an activated releasate, platelet lysate or a cell-reduced factor concentrate. Studies on these product families are therefore not automatically comparable. [1]
Terminology note: In this article, PRP refers exclusively to Platelet-Rich Plasma. “PRP powder” is used as a scientific descriptive term for lyophilized platelet-derived preparations, not as a product or brand name.
The short answer
1
Technically feasible
Multiple research groups have shown that platelet-derived preparations can be freeze-dried and later reconstituted. Under suitable process conditions, selected growth factors and biological activities can be retained.
2
Not identical to fresh PRP
Lyophilization changes the product. In da Silva et al., for example, only about 54% of platelets were described as intact after drying even though several measured growth factors remained comparable.
3
Not clinically standardized
Human data exist, but direct clinical evidence is small and heterogeneous compared with the process research. General superiority over fresh PRP has not been demonstrated.
Four product families that should not be mixed up
FD
FD-PRP
Freeze-dried PRP designed to preserve as many platelets and platelet functions as possible after reconstitution.
REL
FD releasate
PRP is activated before drying. The target is the soluble released factor pool rather than the intact platelet.
L-HPL
Platelet lysate / L-HPL
Platelets are intentionally lysed and cellular debris is reduced or removed. The lyophilizate mainly contains soluble platelet-derived factors.
PFC
PFC-FD / cell-reduced concentrates
PRP is processed into a non-coagulating or cell-reduced factor fraction and then freeze-dried.
How does a blood-derived preparation become a lyophilizate?
Published methods differ substantially, but they share a common logic: characterize the starting material, generate the intended platelet fraction, define the product mode, formulate it, freeze it under controlled conditions, dry it under vacuum, package and test it, and finally reconstitute it in a defined way. Freeze-drying alone does not turn PRP into a standardized product. [1]
Starting material
PRP / PC
Product mode
Freezing
Vacuum drying
QC + storage
Reconstitution
Important: centrifugation, freezing and drying parameters reported in publications are study- and equipment-specific. They are not a clinical manufacturing instruction.
What do the key studies show?
Shiga 2017 · human FD-PRP [2]
PRP from 12 healthy donors was assessed fresh, frozen or freeze-dried. After eight weeks, the growth factors examined were largely retained in the FD arm. The authors explicitly identified non-sterile preparation as a limitation.
Laboratory / stability
da Silva 2018 · fresh vs lyophilized PRP [3]
VEGF, EGF, TGF-β and PDGF were in similar ranges after lyophilization and fibroblast proliferation was comparable. At the same time, only around 54% of platelets were described as intact.
In vitro
Kieb 2017 · standardized powder [4]
Twelve apheresis platelet concentrates from different donors were pooled into a standardized lyophilized preparation. Pooling can reduce donor variability, but it does not eliminate it.
Method / in vitro
Nakatani 2017 · reconstitution concentration [5]
FD-PRP was reconstituted to the original volume or at a higher concentration. The preclinical model showed that different factor concentrations can be generated. This is a dosing option, not evidence that a higher concentration is clinically superior.
Preclinical
Wendland 2025 · L-HPL [6]
A detailed lyophilization process for human platelet lysate was reported. Eleven measured mediators showed no significant differences between HPL and L-HPL, and tested MSC functions remained comparable. The target is lysate, not intact platelets.
Process development
Ohtsuru 2023 · PFC-FD [7]
312 consecutive patients with knee osteoarthritis received PFC-FD in a prospective, single-arm open study. At 12 months, 62% met OMERACT-OARSI responder criteria. Without a control group, superiority or clear causality cannot be inferred.
Human study, uncontrolled
Can PRP powder be deliberately concentrated?
In principle, yes: a lyophilizate can be reconstituted with different fluid volumes. Nakatani et al. experimentally showed that a smaller reconstitution volume can produce higher concentrations of PDGF-BB and TGF-β1. This is not a general therapeutic dosing recommendation. Osmolality, total protein, coagulation behaviour, local tolerability and the specific formulation must be validated separately. [5]
How strong is the clinical evidence?
The technology is further developed than the clinical evidence. Direct human studies exist, but they are limited in number and investigate different products.
Burn injuries
A small prospective double-blind randomized study of 27 patients examined lyophilized PRP powder in deep second-degree burns and reported better short-term wound-healing endpoints. The sample is too small for broad conclusions. [8]
Knee osteoarthritis
The largest directly relevant human study identified in this review included 312 patients treated with PFC-FD. It was single-arm and open-label, without placebo or fresh-PRP comparison. [7]
Bone, cartilage and wounds
Many additional in-vitro, animal and early clinical studies exist. Evidence for fresh PRP cannot automatically be transferred to a lyophilized or cell-reduced product. [1]
62%
In the open-label PFC-FD study, 62% of evaluated patients met OMERACT-OARSI responder criteria at 12 months. This is a clinical signal, not a controlled efficacy proof. [7]
Where could the advantage lie?
Storage
Freeze-drying can extend the storage window of selected platelet-derived preparations. Actual shelf life remains specific to the product, packaging and validated process.
Standardization
Pooling and defined release criteria can improve batch consistency. Pooling reduces donor variability but does not remove it.
Reconstitution
The final volume can in principle be defined, allowing more controlled concentration if the formulation has been validated for this purpose.
Logistics
Manufacturing and application can be separated in time. That convenience also increases quality, sterility and regulatory requirements.
EU and Germany: more complex than fresh point-of-care PRP
A genuine human PRP or platelet-derived ingredient cannot simply be positioned as a cosmetic in the EU: Annex II entry 416 of the EU Cosmetics Regulation lists cells, tissues or products of human origin among prohibited cosmetic ingredients. [9]
Regulation (EU) 2024/1938 on substances of human origin (SoHO) will largely apply from 7 August 2027 and uses a broad concept of substances of human origin. It also contains interfaces with medicinal-product and other EU frameworks. The regulatory status of a specific lyophilized PRP product therefore depends on the complete manufacturing and use model. [10]
German AMG §13(2b) provides an exemption from a manufacturing authorization for certain medicinal products manufactured under a physician's direct professional responsibility for personal administration to a specified patient. It is not a blanket authorization for centralized manufacturing, shipping, long-term storage or allogeneic/pooled powders. [11]
What remains unresolved?
- There is no internationally accepted standard defining exactly what “PRP powder” is.
- Many products lack direct randomized comparisons with fresh PRP, standard care or placebo.
- Optimal composition, dose and reconstitution are not generally established.
- Residual moisture, packaging, sterility, endotoxins, factor profile and a functional potency assay require product-specific validation.
- Patents and laboratory protocols can demonstrate technical feasibility but not clinical efficacy or regulatory approval.
Conclusion
PRP powder is not science fiction. Freeze-dried platelet-derived preparations are sufficiently described to establish technical feasibility. The decisive question is the product definition: should functional platelets be preserved, or should a standardized releasate or lysate be produced? Only after that decision can quality, stability, dose, clinical evidence and regulatory pathway be assessed coherently.
Further reading on prpmed.de
Selected scientific and regulatory sources
- Andia I et al. Freeze-Drying of Platelet-Rich Plasma: The Quest for Standardization. Int J Mol Sci. 2020;21:6904.
- Shiga Y et al. Freeze-Dried Human Platelet-Rich Plasma Retains Activation and Growth Factor Expression after an Eight-Week Preservation Period. Asian Spine J. 2017.
- da Silva LQ et al. Platelet-rich plasma lyophilization enables growth factor preservation and functionality when compared with fresh platelet-rich plasma. Regen Med. 2018.
- Kieb M et al. Platelet-Rich Plasma Powder: A New Preparation Method for the Standardization of Growth Factor Concentrations. Am J Sports Med. 2017.
- Nakatani Y et al. Efficacy of freeze-dried platelet-rich plasma in bone engineering. Arch Oral Biol. 2017.
- Wendland K et al. Lyophilized human platelet lysate: manufacturing, quality control, and application. Front Cell Dev Biol. 2025.
- Ohtsuru T et al. Freeze-dried noncoagulating platelet-derived factor concentrate in knee osteoarthritis. 2023.
- Yeung CY et al. Efficacy of Lyophilised Platelet-Rich Plasma Powder on Healing Rate in Patients With Deep Second Degree Burn Injury. 2018.
- Regulation (EC) No 1223/2009 on cosmetic products, Annex II, entry 416.
- Regulation (EU) 2024/1938 on substances of human origin (SoHO).
- Arzneimittelgesetz (AMG), § 13.
Editorial note: This article is intended for medical professionals and reviews published research. It is not a manufacturing instruction, treatment recommendation or legal opinion. Current manufacturer instructions, quality requirements and applicable regulatory rules remain decisive for clinical processes.